Tempus AI's stock surged following a Merck and Moderna cancer trial that demonstrated positive results using Personalis technology, which Tempus acquired. The trial outcome validated the company's investment in the Personalis acquisition.
Summaries like this, in your inbox every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Supermicro Computer appointed Mark Long as chief financial officer, bringing an experienced technology finance…
Holtek Semiconductor unveiled its 2026 product roadmap on October 15, focusing on four core areas: smart prote…
TSMC reported about NT$763.1b in Q3 net profit and confirmed that demand for advanced processors is running ah…
Nvidia-backed CoreWeave steadied Thursday after a sharp slump, as investors worried about the debt financing b…
Weathernews said on October 15 it implemented its own AI weather-forecasting model, AI-Nowcast, in its Weather…
TOPPAN Holdings and Keio University ran a quantum-computer and generative-AI proof-of-concept from February 1…
